Journal
FRONTIERS IN IMMUNOLOGY
Volume 5, Issue -, Pages 1-6Publisher
FRONTIERS RESEARCH FOUNDATION
DOI: 10.3389/fimmu.2014.00626
Keywords
immunoglobulin replacement therapy; secondary hypogammaglobulinemia; chronic lymphocytic leukemia; multiple myeloma; bone marrow transplantation; solid organ transplantation; subcutaneous immunoglobulins
Categories
Funding
- CSL Behring
- Baxter
Ask authors/readers for more resources
lmmunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available